Trichomoniasis medical therapy

Jump to navigation Jump to search

Sexually transmitted diseases Main Page

Vaginitis Main Page

Trichomoniasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Trichomoniasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Trichomoniasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Trichomoniasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Trichomoniasis medical therapy

CDC on Trichomoniasis medical therapy

Trichomoniasis medical therapy in the news

Blogs on Trichomoniasis medical therapy

Directions to Hospitals Treating Trichomoniasis

Risk calculators and risk factors for Trichomoniasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]

Overview

Antimicrobial therapy is the standard of care for trichomoniasis in both genders once the diagnosis has been confirmed. The symptoms of trichomoniasis among infected men may disappear within a few weeks even without treatment, but asymptomatic men may continue to be infectious and should therefore be treated. Antimicrobial therapy generally includes either metronidazole or tinidazole 2 g PO in a single dose. Prolonged therapy for 7 days is indicated among patients who fail to respond to the initial course of therapy. Following successful treatment, individuals may still be susceptible to re-infection.

Medical Therapy

Antimicrobial therapy is the standard of care for trichomoniasis in both genders once the diagnosis has been confirmed.[1][2][3] The symptoms of trichomoniasis in infected men may disappear within a few weeks even without treatment, but asymptomatic men may continue to be infectious and should therefore be treated.

Antimicrobial Regimen

  • 1. T. vaginalis infection in women
  • Preferred regimen: Metronidazole 500 mg PO bid for 7 days
  • Alternative regimen: Tinidazole 2 g PO in a single dose
  • Note: Patients should avoid sexual contact until they are fully cured of trichomoniasis
  • Note: Testing for other STIs, including HIV, syphilis, gonorrhea, and chlamydia, should be performed for persons with T. vaginalis.
2. T. vaginalis infection in men
  • Preferred regimen: Metronidazole 2 g PO in a single dose
  • Alternative regimen: Tinidazole 2 g PO in a single dose
  • Note: Patients should avoid sexual contact until they are fully cured of trichomoniasis
  • Note: Testing for other STIs, including HIV, syphilis, gonorrhea, and chlamydia, should be performed for persons with T. vaginalis.
  • 2. T. vaginalis infection in pregnant and lactating Women
  • 2.1 Pregnant women
  • 2.2 Post-partum and Breastfeeding
  • Preferred regimen (1): Metronidazole 500 mg PO bid for 7 days
  • Preferred regimen (2): Tinidazole 2 g PO in a single dose
  • Note (1): Do not breastfeed for 12-24 hrs following Metronidazole and 72 hrs following Tinidazole
  • Note (2): Symptomatic pregnant women, regardless of pregnancy stage, should be tested and considered for treatment.[4] Pregnant women should be advised of the risk and benefits to treatment as infection (definitely) and treatment (possibly)
  • Note (3): Pregnant women with HIV who are treated for T. vaginalis infection should be retested 3 months after treatment.
  • 3. T. vaginalis infection in patients with HIV
  • 4. Persistent or recurrent trichomoniasis[5]
  • 4.1 Treatment failure:
    • 4.1.1 In a woman after completing a regimen and has been re-exposed to an untreated partner
    • 4.1.2 In a woman after completing a regimen and no re-exposure has occurred:
    • 4.1.3 In men after completing a regimen and has been re-exposed to an untreated partner
    • 4.1.4 In men after completing a regimen and no re-exposure has occurred:
    • Preferred regimen (1): Metronidazole 500 mg PO BID for 7 days.
  • 4.2 Nitroimidazole-resistant T. vaginalis
  • Antibiotic susceptibility testing recommended
  • Preferred regimen: Tinidazole or metronidazole 2 g daily for 7 days
  • Alternative regimen (1): high-dose oral tinidazole 2 g daily plus tinidazole 500 mg BID intravaginal for 14 days
  • Alternative regimen (2): If the first failed, high-dose oral tinidazole 1 g TID plus paromomycin 4 g of 6.25% intravaginal paromomycin cream nightly for 14 days.

Treatment of Sexual Partners

  • Sexual partners of patients with trichomoniasis should be treated.[3][6]
  • Patients and their sexual partners should avoid sexual contact until they are fully cured of trichomoniasis.

Follow-up

  • Patients should be re-evaluated at the end of the antimicrobial therapy regimen to determine whether therapy has been successful.
  • Patients should be instructed that they are still susceptible to re-infection.
  • Retesting is recommended for sexually active women within 3 months of treatment for initial infection. If retesting at 3 months is not possible, clinicians should retest whenever persons next seek medical care <12 months after initial treatment. [7]
  • Data are insufficient to support retesting men after treatment.

References

  1. Cudmore SL, Delgaty KL, Hayward-McClelland SF, Petrin DP, Garber GE (2004). "Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis". Clin Microbiol Rev. 17 (4): 783–93, table of contents. doi:10.1128/CMR.17.4.783-793.2004. PMC 523556. PMID 15489348.
  2. Coleman JS, Gaydos CA, Witter F (2013). "Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies". Obstet Gynecol Surv. 68 (1): 43–50. doi:10.1097/OGX.0b013e318279fb7d. PMC 3586271. PMID 23322080.
  3. 3.0 3.1 http://www.cdc.gov/std/tg2015/trichomoniasis.htm, Accessed on September 13, 2016
  4. Trintis, J., et al. "Neonatal Trichomonas vaginalis infection: a case report and review of literature." International journal of STD & AIDS 21.8 (2010): 606-607.
  5. "www.cdc.gov" (PDF).
  6. Kissinger, Patricia, et al. "Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial." Sexually transmitted diseases 33.7 (2006): 445-450.
  7. Van Der Pol, Barbara, et al. "Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women." Journal of Infectious Diseases 192.12 (2005): 2039-2044.


Template:WikiDoc Sources